Santhera Pharmaceuticals Holdings Ltd.
Santhera Pharmaceuticals Holdings.../ CH1276028821 /
SPHDF
2024. 02. 22. 18:23:09
|
Vált.
-
|
Forgalom (db) |
Vétel- |
Eladás- |
Piaci kapitalizáció |
Osztalékh. |
P/E Ráta |
11,7000USD
|
-
|
300 Forgalom: 3 510 |
-Vétel (db): - |
-Eladás (db): - |
130,85 mill.USD |
- |
- |
Cégbemutató
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development of treatments for neuro-ophthalmological, neuromuscular and pulmonary diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and cystic fibrosis (CF). Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein, Serbia and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. Santhera is currently conducting the Phase III SIDEROS trial with Raxone® in patients with Duchenne muscular dystrophy (DMD) in respiratory function decline. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product – omigapil – for congenital muscular dystrophy (CMD), both also areas of high unmet medical need.
Igazgatóság & Felügyelőbizottság
CEO |
Dario Eklund |
Igazgatóság |
Andrew Smith, Günther Metz, Oliver Strub, Stephanie Brown, Shabir Hasham |
Felügyelőbizottság |
Thomas Meier, Patrick Vink, Philipp Gutzwiller |
Cégadat
Név: |
Santhera Pharmaceuticals Holding AG |
Cím: |
Hohenrainstraße 24,CH-4133 Pratteln |
Telefon: |
+41-61-9068950 |
Fax: |
+41-61-9068951 |
E-mail: |
office@santhera.com
|
Internet: |
www.santhera.com |
Ipar: |
Gyógyászat |
Szektor: |
Gyógyszeripar |
Alszektor: |
Gyógyszerek |
Pénzügyi év vége: |
12. 31. |
Közkézhányad: |
87,30% |
IPO dátum: |
- |
Cégnaptár
Naptár 22 | 2024. 05. 28.
Részvénytársasági közgyulés
|